MetaCap

Clene (CLNN) vs XBiotech (XBIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XBiotech (XBIT) has outperformed Clene (CLNN) over the past year, losing 24.1% versus a loss of 62.0%. Over five years, XBIT leads with a -86.5% price change compared with -96.3% for CLNN. XBiotech is the larger company by market cap ($52.7 million vs $50.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLNN-62.03%XBIT-24.12%
+23%-24%-71%
Nov 21, 20251 yearNov 20, 2026
CLNN-96.51%XBIT-86.35%
+10%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLNN versus XBIT key metrics
MetricCLNNXBIT
Share price$3.52$1.73
Market cap$50.69M$52.74M
1-day change+0.57%+2.98%
YTD return-40.03%-27.62%
1-year return-62.03%-24.12%
5-year return-96.28%-86.48%
Forward P/E—13.31
EPS (TTM)$-2.30$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$200.00K—
Revenue growth (YoY)-41.52%—
Net income (latest FY)$-26.17M$-45.54M
Gross margin78.50%—
Operating margin-11541.50%—
Net margin-13086.50%—
52-week high$10.84$2.73
52-week low$3.02$1.61
Distance from 52-week high-67.53%-36.63%
Analyst consensusnone—
Avg. price target upside+814.77%—
Average volume115.06K64.77K
Shares outstanding14.40M30.49M
Employees7687
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XBIT has outperformed CLNN by 37.9 percentage points over the past year.

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About XBiotech

XBIT stock →

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

CLNN vs XBIT FAQ

Which is bigger, Clene or XBiotech?

XBiotech (XBIT) is larger, with a market capitalization of $52.74M compared with $50.69M for Clene (CLNN).

Which stock has performed better over the past year, CLNN or XBIT?

XBIT returned -24.12% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.

Are Clene and XBiotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons